GeoVax Labs, Inc. (GOVX) Revenue History
Annual and quarterly revenue from 2014 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
GOVX Revenue Growth
Revenue Breakdown (FY 2022)
GOVX's revenue distribution by segment and geography for fiscal year 2022
By Product/Segment
GOVX Revenue Analysis (2014–2025)
As of May 8, 2026, GeoVax Labs, Inc. (GOVX) generated trailing twelve-month (TTM) revenue of $2.5 million, reflecting significant decline in growth of -100.0% year-over-year. The most recent quarter (Q4 2025) recorded $0 in revenue.
Looking at the longer-term picture, GOVX's 5-year compound annual growth rate (CAGR) stands at +6.4%, indicating steady revenue expansion. The company achieved its highest annual revenue of $4.0 million in 2024.
Revenue diversification analysis shows GOVX's business is primarily driven by NIH Grants (100%). With over half of revenue concentrated in NIH Grants, the company maintains significant focus in this area while developing other growth vectors.
When compared to Healthcare sector peers including NVAX (-52.5% YoY), IOVA (+34.3% YoY), and DVAX (+26.7% YoY), GOVX has underperformed the peer group in terms of revenue growth. Compare GOVX vs NVAX →
GOVX Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| GOVXCurrent | $2M | -100.0% | +6.4% | -869.3% | |
 NVAX | $1.1B | -52.5% | +118.8% | 50.1% | |
 IOVA | $264M | +34.3% | - | -153.1% | |
 DVAX | $277M | +26.7% | +51.1% | -1.5% | |
 SIGA | $95M | -22.1% | -5.4% | 25.1% | |
 AGEN | $114M | +10.4% | +5.3% | -18.0% |
GOVX Historical Revenue Data (2014–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $2.5M | -37.1% | $2.5M | 100.0% | $-21,639,047 | -869.3% |
| 2024 | $4.0M | - | $3.9M | 97.6% | $-25,144,280 | -635.8% |
| 2023 | $0 | -100.0% | $-20,720,766 | - | $-26,742,939 | - |
| 2022 | $82K | -78.9% | $-9,041,953 | -11090.9% | $-14,028,564 | -17207.5% |
| 2021 | $386K | -78.9% | $386K | 100.0% | $-18,745,823 | -4862.7% |
| 2020 | $1.8M | +55.1% | $1.8M | 100.0% | $-2,816,815 | -154.5% |
| 2019 | $1.2M | +22.1% | $1.2M | 100.0% | $-2,372,493 | -201.8% |
| 2018 | $963K | -10.4% | $-915,652 | -95.1% | $-2,563,000 | -266.1% |
| 2017 | $1.1M | +29.7% | $-942,080 | -87.6% | $-2,174,448 | -202.2% |
| 2016 | $829K | +93.6% | $-1,141,941 | -137.8% | $-3,273,367 | -394.9% |
See GOVX's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs GOVX Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare GOVX vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonGOVX — Frequently Asked Questions
Quick answers to the most common questions about buying GOVX stock.
Is GOVX's revenue growth accelerating or slowing?
GOVX revenue declined -100.0% year-over-year, contrasting with the 5-year CAGR of +6.4%. TTM revenue fell to $2M. This reverses the prior growth trend.
What is GOVX's long-term revenue growth rate?
GeoVax Labs, Inc.'s 5-year revenue CAGR of +6.4% reflects the variable expansion pattern. Current YoY growth of -100.0% is below this long-term average.
How is GOVX's revenue distributed by segment?
GOVX reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2014-2025 are available for download. Segment mix reveals concentration and diversification trends.